Opexa Therapeutics Selected As One Of The "Top 10 Advanced Therapy Projects To Watch"

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced Opexa has been named one of the “Top 10 Advanced Therapy Projects to Watch” by Elsevier Business Intelligence for the second consecutive year. As part of this recognition, Neil K. Warma, Opexa’s President and Chief Executive Officer, will present a company overview at the Therapeutic Area Partnerships meeting taking place on November 19-21, 2014, at the Hyatt Regency Boston. Mr. Warma will present on Thursday, November 20 at 2:25 p.m. E.S.T.

Help employers find you! Check out all the jobs and post your resume.